Methods Individuals with schizophrenia suffer from increased rates of overweight/obesity,
diabetes, and dyslipidemia compared to the general population. Weight gain can be …

Background: The aim of this study was to investigate the influence of classical antipsychotics
and the atypical antipsychotic agent clozapine on glucoseinsulin homeostasis to explain …

BACKGROUND:: A major contributor to mortality inpatients with schizophrenia or
schizoaffective disorder is cardiovascular disease, an important risk factor for which is the …

Obesity is common in schizophrenia. The tendency of many of the newer antipsychotics to
induce weight gain to a larger extent than that of traditional low dose neuroleptics has …

To address the issue of weight gain and abnormal lipid metabolism caused by clozapine
and olanzapine administration in patients with schizophrenia, a qualitative and systematic …

Objective Many studies so far have shown that antipsychotic therapy may have an effect on
the development of metabolic syndrome in patients diagnosed with schizophrenia. Our goal …

Obesity is an evident problem in patients with schizophrenia because it involves serious
risks of health and has major effects on morbidity and mortality. Compared with the general …

Objective Clozapine, an evidence-based treatment of refractory schizophrenia, is associated
with increased weight gain and metabolic dysregulation compared with most antipsychotics …

OBJECTIVE: To compare the effects of clozapine, olanzapine and resperidone on the levels
of body mass index (BMI), leptin, fasting insulin concentration (FINS) and insulin resistance …